Skip to main content

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Research Question:
Is a drug called, Olezarsen, safe in patients with familial chlyomicronemia syndrome (FCS)?

Basic Study Information

Familial Chylomicronemia Syndrome (FCS) is a rare genetic disease that causes high levels of fat in the blood. People with FCS have a high risk of developing pancreatitis, a serious condition that can lead to death. There is no cure for FCS, but treatment can help to manage the condition and reduce the risk of complications. Olezarsen is a new drug that is being developed to treat FCS. It is a type of drug that can block the production of a protein that helps to carry fat in the blood. By blocking the production of this protein, Olezarsen can help to lower fat levels in the blood. The purpose of the study is to determine if the drug is safe and tolerable in participants with FCS previously treated with volanesorsen. Participants will be eligible if they have FCS and are taking or have previously taken the drug Volanesorsen.

Location: University of Rochester School of Medicine
Study Reference #: STUDY00007228

Lead Researcher (Principal Investigator)

Lead Researcher:  Robert Block

Study Contact Information

Study Coordinator: Ionis Pharmaceuticals
Phone: (844) 583-0450

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search